Anika Therapeutics Inc.
Anika Therapeutics Inc. (ANIK): 5 pipeline candidates · ~46 mo cash runway · 2 clinical trials. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
45.5 months
1% dilution
Lead: Approved
5 candidates
N/A
2 buys · 0 sells (180d)
A transparent, data-derived signal for Anika Therapeutics Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$195.9M
Cash
$41.0M
Quarterly Burn
$4.8M
Runway
45.5 mo
Revenue
$29.6M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (5 candidates)
| Drug | Phase |
|---|---|
| cingal | Phase 3 |
| elevess | Approved |
| hyalofast | Phase 3 |
| orthovisc high molecular weight hyaluronan | Approved |
| staarvisc ii | Approved |
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
129
Total value held
$179.0M
| Holder | Shares | Value |
|---|---|---|
| blackrock, inc. | 1,594,893 | $23.1M |
| caligan partners lp | 1,435,130 | $20.8M |
| vanguard capital management llc | 1,211,554 | $17.6M |
| morgan stanley | 872,066 | $12.6M |
| boothbay fund management, llc | 529,503 | $7.7M |
| renaissance technologies llc | 502,217 | $7.3M |
| dimensional fund advisors lp | 458,847 | $6.7M |
| capital management corp /va | 447,721 | $6.5M |
| deutsche bank ag\ | 353,174 | $5.1M |
| state street corp | 346,092 | $5.0M |
Showing top 10 of 129 institutional holders of Anika Therapeutics Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Anika Therapeutics Inc.'s pipeline?
Anika Therapeutics Inc. (ANIK) has 5 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Anika Therapeutics Inc.'s lead drug candidate?
Anika Therapeutics Inc.'s most advanced tracked candidate is cingal (Phase 3) for OA Pain Management.
What is Anika Therapeutics Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Anika Therapeutics Inc. has approximately 45.5 months of cash runway.
What is Anika Therapeutics Inc.'s market capitalization?
Anika Therapeutics Inc.'s market capitalization is approximately $195.9M.
Who is the CEO of Anika Therapeutics Inc.?
Mr. Stephen D. Griffin is the chief executive officer of Anika Therapeutics Inc. (ANIK).
Get the full picture on Anika Therapeutics Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.